Skip to main content
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc — Investor Relations & Filings

Ticker · XFOR ISIN · US0428731097 LEI · 549300R0UFVPXWP86U94 US Manufacturing
Filings indexed 784 across all filing types
Latest filing 2017-11-20 Director's Dealing
Country US United States of America
Listing US XFOR

About X4 Pharmaceuticals, Inc

https://www.x4pharma.com/

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2017-11-20 English
FORM 4 SUBMISSION
Director's Dealing
2017-11-20 English
FORM 4 SUBMISSION
Director's Dealing
2017-11-20 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on amendments to the company's articles of incorporation and bylaws, including changes related to the IPO, board structure, and governance provisions. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document is not a proxy statement or remuneration report, but rather an announcement of corporate governance changes. This fits best under the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management structure. The document length (6230 characters) supports it being a substantive filing rather than a brief announcement. Therefore, the classification is MANG with high confidence.
2017-11-20 English
FORM 3 SUBMISSION
Director's Dealing
2017-11-20 English
FORM 3 SUBMISSION
Director's Dealing
2017-11-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.